Aeterna Zentaris Gmbh

Zentaris Ivp Gmbh

Philippe Bouchard

Jurgen Engel

Klaus Diedrich

Rene Frydman

Paul Devroey

A method for obtaining the production of a fertilizable oocyte within a program of assisted reproduction techniques comprising normal follicular growth and development to proceed in the absence of stimulation by an exogenous gonadotropin, followed by administering an amount of an LHRH antagonist in a dosage regimen that prevents a premature LH surge while maintaining FSH secretion at a natural level and individual estrogen development is not affected.

LHRH&#x2014;antagonists in the treatment of fertility disorders

A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the negative effects of HCG.

Growing community of inventors

Paris, France

Philippe Bouchard